Like many other well-intended programs 340B has ended up both wasting money and failing to provide benefits for patients.
The Case for 340B Reform Is Made on Capitol Hill
At a Capitol Hill briefing on the urgent need for reforms to the 340B Drug Pricing Program, the case was made for prompt action to fix the program. The event took place at the Senate Visitors Center on September 23, 2024, and was hosted by the Council for Citizens Against Government Waste (CCAGW). The panel […]
The 340B Drug Discount Program Needs an Overhaul
CAGW has long been concerned with the misuse of the 340B Program.
New Study Exposes More Exploitation and Waste in the 340B Drug Discount Program
A new study, “The 340B Drug Discount Program Exceeds $100B in 2022,” shows the program is misused.
New Study Confirms 340B Program is Exploited
A new study, “340B and Health Equity: A Missed Opportunity in Medically Underserved Areas,” shows the program is misused.
No Government Price Controls to Pay for Biden’s Gargantuan Spending Bill
Sen. Ron Wyden (D-Ore.) wants to use price controls in Medicare Part D to pay for President Biden’s extravagant spending.
Biden Budget Offers Potential Oversight Tool on 340B Program
The Biden administration’s budget includes new enforcement tools for oversight of the 340B program but the details will matter.
Problems Continue with 340B Program
Berkeley Research Group report shows once again how 340B has been corrupted and is being abused.
Most Favored Nation Policy: Unfavorable to U.S. Pharmaceutical Research
President Trump signs controversial Executive Order (EO) implementing “most favored nation” policy to lower drug costs.
Wasteful Spending on 340B Keeps Growing and Growing
Amid the COVID-19 pandemic response, the 340B drug safety-net program problems seem to have gotten lost.